RU2000107822A - OPTICALLY PURE ANALOGUES OF CAMPTOTECINE, OPTICALLY PURE INTERMEDIATE SYNTHESIS PRODUCT AND METHOD FOR PRODUCING IT - Google Patents
OPTICALLY PURE ANALOGUES OF CAMPTOTECINE, OPTICALLY PURE INTERMEDIATE SYNTHESIS PRODUCT AND METHOD FOR PRODUCING ITInfo
- Publication number
- RU2000107822A RU2000107822A RU2000107822/04A RU2000107822A RU2000107822A RU 2000107822 A RU2000107822 A RU 2000107822A RU 2000107822/04 A RU2000107822/04 A RU 2000107822/04A RU 2000107822 A RU2000107822 A RU 2000107822A RU 2000107822 A RU2000107822 A RU 2000107822A
- Authority
- RU
- Russia
- Prior art keywords
- product
- general formula
- compound
- salt
- formula
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 230000002194 synthesizing Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- -1 tert-butyl ester Chemical class 0.000 claims 4
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N Ethyl radical Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 1
- LOUPRKONTZGTKE-LHHVKLHASA-N Quinidine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 1
- 229940083599 Sodium Iodide Drugs 0.000 claims 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000012429 reaction media Substances 0.000 claims 1
- 235000009518 sodium iodide Nutrition 0.000 claims 1
- 0 *[C@@](CC(OC1)=C)(C(C=CC2)=C1C2P)O Chemical compound *[C@@](CC(OC1)=C)(C(C=CC2)=C1C2P)O 0.000 description 3
- GIHLLCADMYIONN-QVQLZXEVSA-N C=C(C[C@H]1O)OCC(C(C2C3)P)=C1C=C2C(C1)C3=Cc(cc2F)c1cc2F Chemical compound C=C(C[C@H]1O)OCC(C(C2C3)P)=C1C=C2C(C1)C3=Cc(cc2F)c1cc2F GIHLLCADMYIONN-QVQLZXEVSA-N 0.000 description 1
Claims (1)
или тем, что он представляет собой одну из солей соединения формулы (II), такую, например, как соль формулы (III), представленной ниже
2. Соединение по п. 1 в качестве продукта для получения противоопухолевых лекарственных средств.1. Product, characterized in that it meets one of the formulas (I) or (II) below
or the fact that it is one of the salts of the compounds of formula (II), such as, for example, a salt of the formula (III) below
2. The compound according to claim 1 as a product for the production of antitumor drugs.
в которой R обозначает этильный радикал.5. As a new industrial product, a product of the general formula M below,
in which R is an ethyl radical.
в которой R обозначает этильный радикал, отличающийся тем, что он состоит из следующих последовательных стадий: рацемический сложный трет-бутиловый эфир, представленный ниже,
обрабатывают при комнатной температуре в течение 18 часов трифторуксусной кислотой, в результате чего получают соответствующую карбоновую кислоту; затем соль хинидина кислоты, полученной перед этим, нагревают в изопропиловом спирте до температуры выше 30oС, предпочтительно приблизительно 50oС, после чего дают реакционной среде охладиться до комнатной температуры таким образом, что соль одного из энантиомеров указанной кислоты кристаллизуется, в то время как соль другого энантиомера, анион которого представлен ниже, остается в растворе;
раствор незакристаллизовавшейся соли энантиомера в изопропиловом спирте концентрируют, обрабатывают соляной кислотой и перемешивают, получая соединение общей формулы А, представленной ниже;
затем соединение общей формулы А приводят в контакт с палладием на влажном угле, потом к смеси добавляют формиат аммония или муравьиную кислоту, в результате чего получают дебензилированный продукт общей формулы В, представленной ниже;
затем циклизуют соединение общей формулы В путем воздействия дициклогексилкарбодиимидом с получением лактонного соединения общей формулы С, представленной ниже;
наконец, путем воздействия иодидом натрия и триметилсилилхлоридом, превращают группу -ОСН3 лактонного соединения общей формулы С в карбонильную группу с получением соединения общей формулы М, представленной ниже.6. The method of obtaining the product of General formula M below
in which R denotes an ethyl radical, characterized in that it consists of the following successive stages: racemic tert-butyl ester, presented below,
treated at room temperature for 18 hours with trifluoroacetic acid, whereby the corresponding carboxylic acid is obtained; then, the quinidine salt of the acid obtained above is heated in isopropyl alcohol to a temperature above 30 ° C, preferably approximately 50 ° C, after which the reaction medium is allowed to cool to room temperature so that the salt of one of the enantiomers of this acid crystallizes, while as a salt of another enantiomer, the anion of which is presented below, remains in solution;
a solution of the non-crystallized salt of the enantiomer in isopropyl alcohol is concentrated, treated with hydrochloric acid and stirred to obtain a compound of general formula A below;
then the compound of the general formula A is brought into contact with palladium on wet coal, then ammonium formate or formic acid is added to the mixture, whereby a debenzylated product of the general formula B is given below;
then the compound of general formula B is cyclized by exposure to dicyclohexylcarbodiimide to give a lactone compound of general formula C below;
finally, by exposure to sodium iodide and trimethylsilyl chloride, the group —OCH 3 of the lactone compound of the general formula C is converted to a carbonyl group to give the compound of the general formula M below.
7. В качестве лекарственного средства продукт, отличающийся тем, что он отвечает одной из формул (I) или (II), представленных ниже,
или тем, что он представляет собой одну из солей присоединения продукта формулы (II) с фармацевтически приемлемыми минеральными или органическими кислотами, такую как, например, соль формулы (III), представленной ниже,
или любая смесь этих последних.
7. As a medicine, a product characterized in that it meets one of the formulas (I) or (II) below,
or by the fact that it is one of the addition salts of a product of formula (II) with pharmaceutically acceptable mineral or organic acids, such as, for example, a salt of formula (III) below,
or any mixture of these latter.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9710785A FR2768431B1 (en) | 1997-08-29 | 1997-08-29 | NOVEL OPTICALLY PURE CAMPTOTHECIN ANALOGS, A NEW OPTICALLY PURE SYNTHESIS INTERMEDIATE AND PROCESS FOR PREPARING THE SAME |
FR9710785 | 1997-08-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000107822A true RU2000107822A (en) | 2002-01-10 |
RU2233283C2 RU2233283C2 (en) | 2004-07-27 |
Family
ID=9510590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000107822/04A RU2233283C2 (en) | 1997-08-29 | 1998-08-07 | Optically pure analogues of camptothecin, optically pure intermediate product of synthesis and method for its preparing |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP1007527B1 (en) |
JP (1) | JP2001514261A (en) |
KR (1) | KR100570254B1 (en) |
CN (3) | CN1104434C (en) |
AR (1) | AR016856A1 (en) |
AT (1) | ATE253069T1 (en) |
AU (1) | AU760863B2 (en) |
BR (1) | BR9811405A (en) |
CA (1) | CA2301739C (en) |
CZ (1) | CZ297896B6 (en) |
DE (1) | DE69819340T2 (en) |
DK (1) | DK1007527T3 (en) |
ES (1) | ES2209196T3 (en) |
FR (1) | FR2768431B1 (en) |
HK (2) | HK1031732A1 (en) |
HR (1) | HRP20000110A2 (en) |
HU (1) | HUP0003429A3 (en) |
IL (2) | IL134437A0 (en) |
NO (1) | NO324882B1 (en) |
NZ (1) | NZ502862A (en) |
PL (1) | PL195289B1 (en) |
PT (1) | PT1007527E (en) |
RU (1) | RU2233283C2 (en) |
TW (1) | TW419479B (en) |
WO (1) | WO1999011646A1 (en) |
ZA (1) | ZA987445B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2790261B1 (en) * | 1999-02-26 | 2004-09-10 | Sod Conseils Rech Applic | NOVEL OPTICALLY PURE CAMPTOTHECIN ANALOGS AND PROCESSES FOR THEIR PREPARATION |
US6207832B1 (en) | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US6372906B1 (en) | 2001-04-12 | 2002-04-16 | University Of Pittsburgh | Synthesis of silyl camptothecins and silyl homocamptothecins |
US6723853B2 (en) | 2001-08-27 | 2004-04-20 | University Of Pittsburgh | Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins |
CN100408582C (en) * | 2004-02-12 | 2008-08-06 | 中国人民解放军第二军医大学 | Homocamptoth-ecine compounds, their preparation process and use |
CA2580747A1 (en) * | 2004-09-21 | 2006-03-30 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) | Novel processes for the production of useful intermediates |
CN100465175C (en) * | 2005-11-29 | 2009-03-04 | 中国人民解放军第二军医大学 | 7-bit substituted comptothecine kind compound and pharmaceutical use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5459269A (en) * | 1992-06-18 | 1995-10-17 | North Carolina State University | 14-halo-camptothecins |
DK0835258T3 (en) * | 1995-06-21 | 2003-02-03 | Sod Conseils Rech Applic | New Camptothecin Analogs, Methods of Preparation thereof, Their Use as Medicines and Pharmaceutical Preparations Containing These |
-
1997
- 1997-08-29 FR FR9710785A patent/FR2768431B1/en not_active Expired - Fee Related
-
1998
- 1998-08-07 EP EP98941567A patent/EP1007527B1/en not_active Expired - Lifetime
- 1998-08-07 AT AT98941567T patent/ATE253069T1/en active
- 1998-08-07 NZ NZ502862A patent/NZ502862A/en unknown
- 1998-08-07 IL IL13443798A patent/IL134437A0/en active IP Right Grant
- 1998-08-07 DK DK98941567T patent/DK1007527T3/en active
- 1998-08-07 PL PL98338835A patent/PL195289B1/en not_active IP Right Cessation
- 1998-08-07 PT PT98941567T patent/PT1007527E/en unknown
- 1998-08-07 CN CN98808720A patent/CN1104434C/en not_active Expired - Lifetime
- 1998-08-07 ES ES98941567T patent/ES2209196T3/en not_active Expired - Lifetime
- 1998-08-07 CA CA002301739A patent/CA2301739C/en not_active Expired - Fee Related
- 1998-08-07 WO PCT/FR1998/001768 patent/WO1999011646A1/en active IP Right Grant
- 1998-08-07 AU AU89896/98A patent/AU760863B2/en not_active Ceased
- 1998-08-07 CN CNB031021662A patent/CN1195758C/en not_active Expired - Fee Related
- 1998-08-07 JP JP2000508685A patent/JP2001514261A/en active Pending
- 1998-08-07 BR BR9811405-0A patent/BR9811405A/en not_active Application Discontinuation
- 1998-08-07 DE DE69819340T patent/DE69819340T2/en not_active Expired - Lifetime
- 1998-08-07 RU RU2000107822/04A patent/RU2233283C2/en not_active IP Right Cessation
- 1998-08-07 CZ CZ20000711A patent/CZ297896B6/en not_active IP Right Cessation
- 1998-08-07 KR KR1020007002034A patent/KR100570254B1/en not_active IP Right Cessation
- 1998-08-07 EP EP03077049A patent/EP1378512A1/en not_active Withdrawn
- 1998-08-07 HU HU0003429A patent/HUP0003429A3/en unknown
- 1998-08-18 ZA ZA987445A patent/ZA987445B/en unknown
- 1998-08-19 TW TW087113646A patent/TW419479B/en not_active IP Right Cessation
- 1998-08-21 AR ARP980104157A patent/AR016856A1/en active IP Right Grant
-
2000
- 2000-02-08 IL IL134437A patent/IL134437A/en not_active IP Right Cessation
- 2000-02-28 NO NO20000995A patent/NO324882B1/en not_active IP Right Cessation
- 2000-02-29 HR HR20000110A patent/HRP20000110A2/en not_active Application Discontinuation
-
2001
- 2001-04-03 HK HK01102373A patent/HK1031732A1/en not_active IP Right Cessation
-
2003
- 2003-02-08 CN CN03102165A patent/CN1440972A/en active Pending
-
2004
- 2004-02-25 HK HK04101371A patent/HK1058665A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS58172367A (en) | Novel derivative of bicyclic amino acid | |
JPH0665268A (en) | Production of phosphorus-containing l-amino acid, its derivative and intermediate for said production process | |
RU2000107822A (en) | OPTICALLY PURE ANALOGUES OF CAMPTOTECINE, OPTICALLY PURE INTERMEDIATE SYNTHESIS PRODUCT AND METHOD FOR PRODUCING IT | |
US6197998B1 (en) | Process for producing N-glycyltyrosine and its crystal structure | |
EP0588797B1 (en) | N- 4,5-dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-yl]carbonyl]amino acids useful in the therapy of osteoarticular affections | |
JP2778103B2 (en) | Method for producing optically active threodihydroxyphenylserine derivative | |
RU2004124840A (en) | SOLID SALTS OF BENZAZEPINE COMPOUNDS AND THEIR APPLICATION FOR PRODUCTION OF PHARMACEUTICAL COMPOUNDS | |
DE2059985B2 (en) | Right-handed, basic substituted phenylacetonitriles, processes for their preparation and pharmaceuticals containing these compounds | |
CA2301739A1 (en) | Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same | |
HU205356B (en) | Process for producing n-(5,6,7,8-tetrahydropyrido/2,3-d/pyrimidin-6-ylalkanoyl)-glutamic acid derivatives and pharmaceutical compositions comprising same | |
JP2572774B2 (en) | Method for synthesizing carboxylic acid | |
JP2579744B2 (en) | Intermediates for the production of bicyclic amino acid derivatives of ACE inhibitors | |
JPS606958B2 (en) | Antibiotic purification method | |
CN1080286A (en) | Has new aminocarboxylic acid derivative of antianaphylaxis and anti-asthmatic action and preparation method thereof | |
Schjelderup et al. | The absolute configuration of oxyphencyclimine, a parasympatholytic drug. Syntheses of both enantiomers | |
KR20090056527A (en) | Improved process for the preparation of atorvastatin calcium salt | |
KR100372759B1 (en) | Novel Chiral Ligand and Process for Preparing (2R,3R)-2,3-dialkyltartaric Acid Employing the Same | |
JPH0415787B2 (en) | ||
JP2002540101A (en) | Synthesis of 3-amino-3-aryl propionate | |
JP2636013B2 (en) | Bis (methylenedioxy) biphenyl compound | |
US4341773A (en) | 2,4-Diamino-5-sulfamoylbenzene sulfonic acids and process for their manufacture | |
KR840000912B1 (en) | Process for preparing "2,4-diamino-5-sulfamoyl benzene sulfonic acids | |
JPH0798802B2 (en) | Process for producing optically active indoline-2-carboxylic acid | |
KR100372758B1 (en) | Novel Chiral Ligand and Process for Preparing (2S,3S)-2,3-dialkyltartaric Acid Employing the Same | |
US4593107A (en) | 5-acetyloxy-L-tryptophane and preparation method thereof |